# Pomerantz LLP

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/pomerantz-llp
Canonical HTML page: https://getbiobrief.com/entity/pomerantz-llp

## Timeline

- **2026-05-22**: Lead Plaintiff Deadline — Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.
- **2026-03-23**: Follow-up Disclosure — Secondary announcements highlight the filing and the process for shareholders to join the litigation.
- **2026-03-22**: Class Action Announcement — Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.
- **2026-03-21**: Litigation Filed — Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
- **2022-04-18**: Partnership Termination — BMS and Nektar officially end their global clinical development collaboration.
- **2022-03-14**: Phase 3 Failure — Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
- **2018-02-14**: BMS Partnership — Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.

## Recent coverage (4 stories)

### GeneDx Impairment Sparks Biotech Securities Suit: $31.3M Charge on AI Acquisition
2026-06-15 03:31:31 · Sentiment: Negative · Impact: 6/10 · Sources: 6

A $31.3 million impairment on the Fabric Genomics deal has drawn a securities lawsuit against GeneDx. For biotech investors, the case highlights the perils of overvalued AI acquisitions in genomics, as GeneDx trimmed its revenue forecast by up to $80 million.
Full story: https://getbiobrief.com/story/genedx-securities-lawsuit-bio-impairment

### Boston Scientific Faces Class Action Scrutiny Over Securities Disclosures
2026-03-23 23:33:15 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.
Full story: https://getbiobrief.com/story/boston-scientific-class-action-pomerantz-llp

### Pomerantz LLP Advances Class Action Against Mereo BioPharma Over Disclosures
2026-03-22 02:55:33 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pomerantz LLP has issued a formal reminder regarding a class-action lawsuit filed against Mereo BioPharma Group plc, alleging potential violations of federal securities laws. The legal action focuses on whether the company made misleading statements or failed to disclose material facts regarding its clinical operations and financial outlook.
Full story: https://getbiobrief.com/story/pomerantz-llp-mereo-biopharma-class-action

### Pomerantz LLP Files Class Action Against Nektar Therapeutics Over Disclosures
2026-03-22 02:52:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Full story: https://getbiobrief.com/story/nektar-therapeutics-class-action-litigation-pomerantz

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.